Marcelo C Pasquini, MD | Medical College of Wisconsin

Marcelo C. Pasquini, MD

Associate Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Medical Oncology

Languages

English, Spanish, Portuguese

Secondary Appointments

Internal Medicine
Hematology

Contact Information

(414) 805-0505

Education

MD - Doctor of Medicine

Biography

Marcelo C. Pasquini, MD, MS, is Associate Professor of Medicine in the Division of Hematology and Oncology. He completed medical school at the State University of Londrina, Brazil; postgraduate training in Internal Medicine at the University of Miami/Jackson Memorial Hospital; Hematology and Oncology at the University of Utah; and Blood and Marrow Transplantation at the Medical College of Wisconsin. He received his Masters of Science degree in Epidemiology from the Medical College of Wisconsin. Dr. Pasquini also serves as Senior Scientific Director for Clinical Trials at the Center for International Blood and Marrow Transplant Research (CIBMTR) where he focuses on clinical research in the field of transplantation.

Research Interests

His medical practice is focused on hematologic malignancies, including multiple myeloma, acute myeloid leukemia, myelodysplasia and the use of blood and marrow transplantation for treatment of these diseases.

Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries.

(Zinter MS, Logan BR, Fretham C, Sapru A, Abraham A, Aljurf MD, Arnold SD, Artz A, Auletta JJ, Chhabra S, Copelan E, Duncan C, Gale RP, Guinan E, Hematti P, Keating AK, Marks DI, Olsson R, Savani BN, Ustun C, Williams KM, Pasquini MC, Dvorak CC.) Biol Blood Marrow Transplant. 2020 Feb;26(2):333-342 PMID: 31563573 PMCID: PMC6943183 SCOPUS ID: 2-s2.0-85074484312 09/30/2019
Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

(Holstein SA, Al-Kadhimi Z, Costa LJ, Hahn T, Hari P, Hillengass J, Jacob A, Munshi NC, Oliva S, Pasquini MC, Shi Q, Stadtmauer EA, Waldvogel SL, McCarthy PL.) Biol Blood Marrow Transplant. 2020 Jan;26(1):e7-e15 PMID: 31526843 PMCID: PMC6942175 SCOPUS ID: 2-s2.0-85073734108 09/19/2019
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.

(Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME.) J Clin Oncol. 2019 Dec 20:JCO1903011 PMID: 31860405 12/21/2019
Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation.

(Sabloff M, Chhabra S, Wang T, Fretham C, Kekre N, Abraham A, Adekola K, Auletta JJ, Barker C, Beitinjaneh AM, Bredeson C, Cahn JY, Diaz MA, Freytes C, Gale RP, Ganguly S, Gergis U, Guinan E, Hamilton BK, Hashmi S, Hematti P, Hildebrandt G, Holmberg L, Hong S, Lazarus HM, Martino R, Muffly L, Nishihori T, Perales MA, Yared J, Mineishi S, Stadtmauer EA, Pasquini MC, Loren AW.) Biol Blood Marrow Transplant. 2019 Dec;25(12):2398-2407 PMID: 31473319 SCOPUS ID: 2-s2.0-85072691397 09/02/2019
Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.

(Solomon SR, St Martin A, Shah NN, Fatobene G, Al Malki MM, Ballen KK, Bashey A, Bejanyan N, Bolaños Meade J, Brunstein CG, DeFilipp Z, Champlin RE, Fuchs EJ, Hamadani M, Hematti P, Kanakry CG, McGuirk JP, McNiece IK, Ciurea SO, Pasquini MC, Rocha V, Romee R, Patel SS, Vasu S, Waller EK, Wingard JR, Zhang MJ, Eapen M.) Blood Adv. 2019 Oct 08;3(19):2836-2844 PMID: 31582392 PMCID: PMC6784523 SCOPUS ID: 2-s2.0-85073446898 10/05/2019
Multiple functional variants in the region are pretransplant markers for risk of GVHD and infection deaths.

(Karaesmen E, Hahn T, Dile AJ, Rizvi AA, Wang J, Wang T, Haagenson MD, Preus L, Zhu Q, Liu Q, Yan L, Liu S, Haiman CA, Stram D, Pooler L, Sheng X, Van Den Berg D, Brock G, Webb A, McCarthy PL, Pasquini MC, Spellman SR, Lee SJ, Paczesny S, Sucheston-Campbell LE.) Blood Adv. 2019 Aug 27;3(16):2512-2524 PMID: 31455667 PMCID: PMC6712530 SCOPUS ID: 2-s2.0-85072287558 08/29/2019
Fludarabine/busulfan conditioning based allogeneic hematopoietic cell transplantation for myelofibrosis: Role of ruxolitinib in improving survival outcomes.

(Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN.) Biol Blood Marrow Transplant. 2020 Jan 23 PMID: 31982543 01/27/2020
Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation?

(Dreger P, Fenske TS, Montoto S, Pasquini MC, Sureda A, Hamadani M, European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR).) Biol Blood Marrow Transplant. 2020 Jan 07 PMID: 31917272 SCOPUS ID: 2-s2.0-85079050617 01/10/2020
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial.

(Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, Logan B, Lowsky R, Qazilbash MH, Sahebi F, Somlo G, Rowley S, Vogl DT, Vesole DH, Pasquini M, Stadtmauer E.) Biol Blood Marrow Transplant. 2019 Nov 19 PMID: 31756536 SCOPUS ID: 2-s2.0-85077165933 11/23/2019
Correction: Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries.

(Muhsen IN, Hashmi SK, Niederwieser D, Kroeger N, Agrawal S, Pasquini MC, Atsuta Y, Ballen KK, Seber A, Saber W, Kharfan-Dabaja MA, Rasheed W, Okamoto S, Khera N, Wood WA, Koh MBC, Greinix H, Kodera Y, Szer J, Horowitz MM, Weisdorf D, Aljurf M.) Bone Marrow Transplant. 2019 Oct 15 PMID: 31616063 SCOPUS ID: 2-s2.0-85074047416 10/17/2019
Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries.

(Muhsen IN, Hashmi SK, Niederwieser D, Kroeger N, Agrawal S, Pasquini MC, Atsuta Y, Ballen KK, Seber A, Saber W, Kharfan-Dabaja MA, Rasheed W, Okamoto S, Khera N, Wood WA, Koh MBC, Greinix H, Kodera Y, Szer J, Horowitz MM, Weisdorf D, Aljurf M.) Bone Marrow Transplant. 2019 Sep 04 PMID: 31484992 SCOPUS ID: 2-s2.0-85073779919 09/06/2019
Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations.

(Aljurf M, Weisdorf D, Hashmi SK, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Ali Hamidieh A, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas M, Ahmed SO, Novitsky N, Srivastava A, Seber A, Elsolh H, Ghavamzadeh A, Confer D, Kodera Y, Greinix H, Szer J, Horowitz M, Niederwieser D.) Hematol Oncol Stem Cell Ther. 2019 Aug 20 PMID: 31449781 08/27/2019